Showing 1 - 5 results of 5 for search 'Martin Reck, MD', query time: 0.04s
Refine Results
-
1
RELAY, Erlotinib Plus Ramucirumab in Untreated, EGFR-Mutated, Metastatic NSCLC: Outcomes by EGFR Exon 19 Deletion Variants by Kazumi Nishino, MD, PhD, Jin-Yuan Shih, MD, PhD, Kazuhiko Nakagawa, MD, PhD, Martin Reck, MD, PhD, Edward B. Garon, MD, Michelle Carlsen, MS, Tomoko Matsui, Carla Visseren-Grul, MD, Ernest Nadal, MD, PhD
Published 2024-02-01
Article -
2
Daratumumab Plus Atezolizumab in Previously Treated Advanced or Metastatic NSCLC: Brief Report on a Randomized, Open-Label, Phase 1b/2 Study (LUC2001 JNJ-54767414) by Rathi N. Pillai, MD, Suresh S. Ramalingam, MD, Meena Thayu, MD, Patricia Lorenzini, RN, Diana A. Alvarez Arias, PhD, Christopher Moy, MS, Natalie Hutnick, PhD, Roland Knoblauch, MD, Huaibao Feng, PhD, Colleen Kane, PhD, Leora Horn, MD, Martin Reck, MD, Santiago Ponce, MD
Published 2021-02-01
Article -
3
Brief Report: A Blood-Based MicroRNA Complementary Diagnostic Predicts Immunotherapy Efficacy in Advanced-Stage NSCLC With High Programmed Death-Ligand 1 Expression by Timothy Rajakumar, MD, PhD, Rastislav Horos, PhD, Paul Kittner, BSc, Mustafa Kahraman, PhD, Tobias Sikosek, PhD, Franziska Hinkfoth, MSc, Kaja Tikk, PhD, Nathaniel D. Mercaldo, PhD, Albrecht Stenzinger, MD, Klaus F. Rabe, MD, PhD, Martin Reck, MD, Michael Thomas, MD, Petros Christopoulos, MD, PhD, Bruno R. Steinkraus, PhD
Published 2022-08-01
Article -
4
RELAY+: Exploratory Study of Ramucirumab Plus Gefitinib in Untreated Patients With EGFR-Mutated Metastatic NSCLC by Makoto Nishio, MD, PhD, Kazuto Nishio, MD, PhD, Martin Reck, MD, PhD, Edward B. Garon, MD, Fumio Imamura, MD, PhD, Tomoya Kawaguchi, PhD, Hiroyuki Yamaguchi, MD, PhD, Satoshi Ikeda, MD, PhD, Katsuya Hirano, MD, Carla Visseren-Grul, MD, Matteo Ceccarelli, PharmD, MS, Sameera R. Wijayawardana, PhD, Annamaria Zimmermann, MS, Tomoko Matsui, Sotaro Enatsu, MD, PhD, Kazuhiko Nakagawa, MD, PhD
Published 2022-04-01
Article -
5
Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC by Marina C. Garassino, MD, Shirish Gadgeel, MD, Silvia Novello, MD, PhD, Balazs Halmos, MD, Enriqueta Felip, MD, Giovanna Speranza, MD, Rina Hui, PhD, Edward B. Garon, MD, Hidehito Horinouchi, MD, PhD, Shunichi Sugawara, MD, PhD, Delvys Rodriguez-Abreu, MD, PhD, Martin Reck, MD, Razvan Cristescu, PhD, Deepti Aurora-Garg, PhD, Andrey Loboda, PhD, Jared Lunceford, PhD, Julie Kobie, PhD, Mark Ayers, MS, Bilal Piperdi, MD, M. Catherine Pietanza, MD, Luis Paz-Ares, MD, PhD
Published 2023-01-01
Article